ITM2A as a potential prognostic marker for triple-negative breast cancer
Authors:
Open Access
- 23 June 2025
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 16 (9) , 2903-2916
Abstract
Different subtypes of breast cancer pose great challenges for precision therapy, especially triple-negative breast cancer (TNBC), because it lacks effective therapeutic targets and is highly resistant to chemotherapy. In this study, the transmembrane protein ITM2A was systematically identified as a novel prognostic biomarker and potential therapeutic target for TNBC. ITM2A was found to be significantly under expressed in TNBC tissues, as revealed by differential expression profiling. Furthermore, patients exhibiting low ITM2A expression demonstrated worse overall survival (OS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS). A combined multi-omics analysis revealed a significant association between low ITM2A expression and immunosuppressive microenvironmental features. It is noteworthy that the ITM2A high-expression group exhibited substantial clinical benefits in anti-PD-L1 treatment (AUC=0.982) and CAR-T treatment (AUC=0.827). Gene Ontology functional annotation and KEGG pathway enrichment analysis indicated that ITM2A may coordinate anti-tumor immune responses by regulating copper ion metabolic reprogramming and immune checkpoint networks. Pharmacogenomic analysis further confirmed that the expression level of ITM2A was negatively correlated with the sensitivity of etoposide. By establishing the 'immunometabolism-therapeutic response' regulatory axis of ITM2A, this study hopes to provide an innovative theoretical basis for the targeted treatment of TNBC and the precise stratification of immunotherapy.Keywords
This publication has 51 references indexed in Scilit:
- S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancerExperimental and Molecular Pathology, 2015
- NCBI GEO: archive for functional genomics data sets—updateNucleic Acids Research, 2012
- ATP7A-related copper transport diseases—emerging concepts and future trendsNature Reviews Neurology, 2011
- S100P: a novel therapeutic target for cancerAmino Acids, 2010
- In vitro studies on Itm2a reveal its involvement in early stages of the chondrogenic differentiation pathwayBiology of the Cell, 2004
- Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinomaCancer Letters, 2003
- Collagenase-3 (MMP-13) and Integral Membrane Protein 2a (Itm2a) are Marker Genes of Chondrogenic/Osteoblastic Cells in Bone Formation: Sequential Temporal, and Spatial Expression of Itm2a, Alkaline Phosphatase, MMP-13, and Osteocalcin in the MouseJournal of Bone and Mineral Research, 2000
- Itm2a Is Induced during Thymocyte Selection and T Cell Activation and Causes Downregulation of Cd8 When Overexpressed in Cd4+Cd8+ Double Positive ThymocytesJournal of Experimental Medicine, 1999
- Genomic organization and chromosomal localization of the Itm2a geneMammalian Genome, 1999
- Etoposide: four decades of development of a topoisomerase II inhibitorEuropean Journal of Cancer, 1998